Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma

Wang, Wei; Chen, Xiaolong; Zhao, Shenyu; Xu, Yiqing; Zhang, Weihan; Liu, Kai; Chen, Xin-Zu; Yang, Kun; Zhang, Bo; Chen, Zhuo; Chen, Jiaping; Zhou, Zong‐Guang; Hu, Jian-Kun

doi:10.18632/oncotarget.8770

Cited by 61 publications

(49 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in patients with stage IV gastric cancer, CTM positivity significantly correlated with the serum CA125 level. In a previous study, serum CA125 is identified as an independent prognostic factor in patients with gastric cancer [40]. CA125 is also known as the mucin MUC16.…”

Section: Discussionmentioning

confidence: 94%

Detection of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer

Zheng

Фан

Zhou

et al. 2017

Translational Oncology

View full text Add to dashboard Cite

PURPOSE: Gastric cancer studies indicated a potential correlation between circulating tumor cells (CTCs) in peripheral blood and tumor relapse/metastasis. The prevalence and significance of circulating tumor microemboli (CTM) in gastric cancer remain unknown. We investigated the prevalence and prognostic value of CTCs and CTM for progression-free survival (PFS) and overall survival (OS) in gastric cancer patients. METHODS:Eighty-one gastric cancer patients consented to provide 5 ml of peripheral blood before systematic therapy. CTCs and CTM were isolated using isolation by size of epithelial tumor cells and characterized by cytopathologists. For 41 stage IV gastric cancer patients, CTM was investigated as a potential biomarker to predict prognosis. RESULTS:CTCs were detected in 51 patients; the average count was 1.81. In clinical stage I, II, III, and IV patients, the average CTC counts were 1.40, 0.67, 1.24, and 2.71, respectively. CTM were detected in 3 of 33 clinical stage I to IIIb patients, at an average of 0.12 (0-2). CTM were detected in 13 of 53 clinical stage IIIc to IV patients, at an average of 1.26 (0-22). In stage IV patients, CTM positivity correlated with the CA125 level. PFS and OS in CTM-positive patients were significantly lower than in CTM-negative patients (P < .001). CTM positivity was an independent factor for determining the PFS (P = .016) and OS (P = .003) of stage IV patients in multivariate analysis. Using markers of the epithelial-mesenchymal transition, single CTCs were divided into three phenotypes including epithelial CTCs, biphenotypic epithelial/mesenchymal CTCs, and mesenchymal CTCs. For CTM, CK−/Vimentin+/CD45− and CK+/Vimentin+/CD45− phenotypes were observed, but the CK+/Vimentin−/CD45− CTM phenotype was not. CA125 was detected in gastric cancer cell lines BGC823 and MGC803. CONCLUSIONS: In stage IV patients, CTM positivity was correlated with serum CA125 level. CTM were an independent predictor of shorter PFS and OS in stage IV patients. Thus, CTM detection may be a useful tool to predict prognosis in stage IV patients.

show abstract

Section: Discussionmentioning

confidence: 94%

Detection of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer

Zheng

Фан

Zhou

et al. 2017

Translational Oncology

View full text Add to dashboard Cite

show abstract

“…As for possible explanations of the gap of CEA levels between GC tissues and the sera, there have been several reports that the amount of CEA released into the circulation does not depend mainly on the tissue CEA level, but depends on distribution patterns within the cancerous tissues, tumor differentiation and lymphovascular invasion [29][30][31] ducted immunohistochemical analysis and found that the appearance of CEA in the surrounding stroma led to the elevation of blood CEA levels due to the abnormal distribution of CEA on the basolateral plasma membrane of colorectal cancer cells [32]. Although previous studies demonstrated that CEA-producing GC and CA19-9-producing GC have different characteristics in morphology, histopathology and metastatic preference, the prognostic values of serum CEA and CA19-9 are still under debate [5,6,9,14].…”

Section: Discussionmentioning

confidence: 99%

“…Whether serum CEA and CA19-9 levels contribute as prognostic indicators for patients with GC has long been discussed, but the results have been rather mixed [10,11]. Inconsistencies in the criteria used for patient inclusion and analyses and different variables (e.g., early detection or prognostic factors) are cited as possible explanations of the conflicting data [12][13][14]. In addition, advances in measurement technology, increased prevalence of early-stage GC, and changes in standard of care such as application of adjuvant therapies may also have caused changes in the clinical significance of serum CEA and CA19-9 over time [15][16][17].…”

mentioning

confidence: 99%

“…In addition, advances in measurement technology, increased prevalence of early-stage GC, and changes in standard of care such as application of adjuvant therapies may also have caused changes in the clinical significance of serum CEA and CA19-9 over time [15][16][17]. Moreover, most published studies focus only on preoperative values of serum tumor markers [6,14]. Thus, there may be room for further evaluating the relevance of these tumor markers using data from the modern era, which include serum values obtained during the postoperative follow-up.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Perioperative Serum Carcinoembryonic Antigen Levels Predict Recurrence and Survival of Patients with Pathological T2-4 Gastric Cancer Treated with Curative Gastrectomy

et al. 2017

View full text Add to dashboard Cite

Background/Aims: Do serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 levels serve as prognostic indicators in patients with gastric cancer (GC)? This is a question that has long been disputed. The aim of this study was to evaluate the significance of perioperative serum levels of CEA and CA19-9 for predicting the recurrence and long-term survival after patients with pT2-4 GC undergo curative gastrectomy. Methods: This study included 251 patients with radically resected pT2-4 GC without preoperative treatment. Associations between the preoperative and postoperative serum levels of CEA or CA19-9 and postoperative long-term outcomes and recurrence patterns were evaluated. Results: Preoperative CEA >5.0 ng/mL was an independent prognostic factor of overall survival. Elevation of both preoperative CEA and CA19-9 levels showed no synergistic adverse effects on prognosis. Preoperative levels of these markers achieved superior predictive performance compared with the postoperative values. Adverse prognosis is significantly associated with persistent elevation of CEA levels before and after gastrectomy. Elevation of CEA levels, particularly at postoperative measurement, was significantly associated with hematogenous recurrence. Conclusion: Determination of perioperative CEA levels facilitated predictions of recurrence patterns and prognosis among patients with pT2-4 GC who underwent curative gastrectomy.

show abstract

“…A recent study from India showed a sensitivity of 42% and a negative predictive value of 63.29% for CA 19-9 in GC [32]. In a more recent study, Wang et al [33] enrolled more than 1,600 patients with GC who underwent gastrectomy and were divided into training and validation cohorts. They discovered positive rates of 20.0, 42.3, and 19.2% for preoperative CA 19-9, CA 125, and CEA, respectively.…”

Section: Ca 19-9 In Gcmentioning

confidence: 99%

Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 72-4 in Gastric Cancer: Is the Old Band Still Playing?

Kotzev¹,

Draganov

2018

Gastrointest Tumors

View full text Add to dashboard Cite

Background: Gastric cancer (GC) is characterized by aggressive behavior and a high mortality rate. The diagnosis of GC is challenging because the GC is often diagnosed in an advanced stage. The use of tumor markers is a putative way to improve the detection and treatment in patients with GC. Summary: In this article, we review the significance of serum carbohydrate antigen (CA) 19-9, carcinoembryonic antigen (CEA), and CA 72-4 in GC. The results from different studies regarding the diagnostic and prognostic role of CA 19-9, CEA, and CA 72-4 in GC are encouraging, but inadequate sensitivity and specificity obstruct their use as standardized and unconditionally reliable markers in GC. New prospective clinical trials are mandatory for clarifying their value in GC. Key Message: CA 19-9, CEA, and CA 72-4 should not be used for screening and early diagnosis in GC, whereas they are beneficial in the detection of late GC. CA 19-9, CEA, and CA 72-4 could be used as prognostic and monitoring tools in GC, and their combined measurement in shorter periods of time is the best method to increase sensitivity and specificity. Practical Implications: Serum CA 19-9, CEA, and CA 72-4 are useful diagnostic and prognostic tumor markers in GC.

show abstract

Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma

Cited by 61 publications

References 31 publications

Detection of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer

Detection of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer

Perioperative Serum Carcinoembryonic Antigen Levels Predict Recurrence and Survival of Patients with Pathological T2-4 Gastric Cancer Treated with Curative Gastrectomy

Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 72-4 in Gastric Cancer: Is the Old Band Still Playing?

Contact Info

Product

Resources

About